Statin dan risiko hiperglikemia: studi praklinis post-market terkontrol

Abstract

Statin is highly effective in preventing atherosclerosis-cardiovascular disease due to lipid abnormality. However, the current observational study showed statin association with new-onset diabetes mellitus, although the data is still conflicting. Until recently, no controlled study compared all statin drugs with this adverse event. The study aimed to determine the statin effect on blood glucose at a moderate dose for rats within 60 days. The animals were divided into 8 groups, and each group contained three mice, namely negatives (CMC 1%), simvastatin (0.052 mg/20 g BW of mice), atorvastatin (0.104 mg/20 g BW of mice), lovastatin (0.052 mg/20 g BW of mice), pitavastatin (0.010 mg/20 g BW of mice), pravastatin (0.052 mg/20 g BW of mice), rosuvastatin (0.052 mg/20 g BW of mice), and fluvastatin (0.208 mg/20 g BW of mice). The blood glucose test was carried out on days 30th and 60th. The results showed no significant difference in the blood glucose between the negatives group and all statin groups on days 30th and 60th. However, an increase in blood glucose on day 30th for pitavastatin, pravastatin, and rosuvastatin as much as 7.08%, 6.29%, and 6.29%, respectively. Moreover, an increase on day 60th for pravastatin, rosuvastatin, fluvastatin, atorvastatin lovastatin, and simvastatin as much as 36.83%, 27.59%, 26.32%, 18.05%, 17.89% dan 10.97%, respectively. This study failed to prove blood glucose elevation associated with a statin. The longer use of drugs was associated with blood glucose level elevation, except for pitavastatin. Therefore, further studies with a long term of statin administration are necessary.